Abstract
Reported rates of BRAF mutation in Irish cutaneous melanoma cohorts are lower than the reported international data. We aimed to assess the mutational status of a cohort of primary cutaneous melanomas and to correlate it with clinical follow-up data.
A total of 92 cases of primary cutaneous melanoma diagnosed at a single institution in 2012 were analyzed. Regions containing common mutations in the BRAF, NRAS, KIT, and KRAS genes were investigated by PCR amplification followed by Sanger sequencing. Demographic details, tumor characteristics, and 10-year outcome data were also obtained.
Ten cases with BRAF V600E mutations (11.6%) and five (5.49%) NRAS mutations (4 at Q61R, 1 at Q61K) were detected. No statistically significant differences were noted between groups for age, gender, depth of invasion, nodal status, or recurrence status (p ≥ 0.05).
These findings suggest that the Irish population has a markedly lower incidence of BRAF and NRAS mutations in melanoma than those reported in other cohorts.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Melanoma is the fifth most commonly diagnosed cancer in Ireland, and its incidence is projected to increase significantly by 2040 [1].
Accurate identification of BRAF mutations has both prognostic and treatment implications [2].
Rates of BRAF mutation in published Irish cohorts have ranged from 19 to 29% [3,4,5]. This is significantly lower than reported international data which suggests a range from 40 to 60% [5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24]. The reasons for this difference are not well understood.
We aimed to assess the mutational status of a cohort of primary cutaneous melanomas diagnosed in an Irish tertiary referral center and to correlate these findings with clinical follow-up data.
Materials and methods
With institutional review board approval; all 132 cases of primary cutaneous melanoma that were diagnosed in Cork University Hospital in the year 2012 were reviewed.
After microdissection, 92 cases progressed to DNA extraction from formalin-fixed, paraffin-embedded (FFPE) blocks using the High Pure FFPET DNA Isolation kit (Roche). Cases that did not progress included consultation cases from outside institutions (n = 23), those without sufficient residual tissue for further testing, or invasive melanomas so focal that microdissection was not possible.
Regions containing common mutations or variations in the BRAF (G469, E586, E597, V600, V601), KRAS (G12, G13), KIT (L576), and NRAS (G12, G13, D38, A59, Q61, K117, A146) genes were investigated by polymerase chain reaction (PCR) amplification followed by Sanger sequencing.
For validation, results were cross-referenced in cases where molecular testing for clinical purposes for BRAF V600 had also occurred.
Demographic details, histopathologic tumor characteristics (as recorded in synoptic summaries), and 10-year outcome data were also obtained.
Comparisons between groups including t-tests and Fisher’s exact tests for continuous and categorical data, respectively, were calculated using the GraphPad QuickCalcs [25].
Results
Ninety-two cases of melanoma occurring in 91 different patients were included. Patients had a mean age of 60.9 years (± 17.5) and 48.9% were male. The most commonly seen melanoma subtype was superficial spreading (n = 57). The mean depth of invasion was 1.93 mm (± 3.5 mm).
Five patients had positive lymph nodes at the time of diagnosis; three were detected by sentinel lymph node sampling and two were detected clinically. One patient (with wild-type disease) had metastatic disease at diagnosis (pleural effusion positive for melanoma).
Ten other patients subsequently developed metastatic disease during the 10-year follow-up period (two of whom were positive for BRAF V600E and two of whom were positive for NRAS Q61R). One patient with wild-type disease developed liver metastases 10 years post-diagnosis; in all other cases, the metastases initially presented in lymph nodes.
Sequencing for variants in the genes of interest was successfully completed as follows: BRAF (n = 89), KRAS (n = 46), KIT (n = 44), and NRAS (n = 91), respectively. Technical and sample availability issues precluded testing of all variants in some cases (Table 1).
BRAF V600 testing detected 10 (11.6%) cases with a pathogenic mutation. All identified pathogenic mutations were in V600E GTG>GAG (NM_004333.6:c.1799T>A).
NRAS testing showed 5 cases with a mutation; 4 of which had a Q61R CAA>CGA mutation (NM_002524.5:c.182A>G), and 1 of which had a Q61K CAA>AAA (NM_002524.5:c.181C>A) mutation).
No variants were identified in cases tested for KRAS G12 or G13 or KIT L576 but the sequencing success rate was only 47–50% (Table 1).
NRAS and BRAF mutations were mutually exclusive in all cases where both were successfully sequenced (n = 78). In all cases, a single mutation was detected.
No statistically significant differences were noted between the mutated or wild-case molecular groups for any of the mutations in terms of age, gender, depth of invasion, nodal status, or recurrence status (p ≥ 0.05) (Table 2).
No discordant results were observed in cases where molecular testing for clinical purposes for BRAF V600 was performed (n = 13).
Discussion
As illustrated in Table 3, the internationally quoted incidence of BRAF mutations in melanoma of primary cutaneous origin is 40–71%, including among other predominantly white populations [5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24]. Furthermore, some studies with reports of low incidence of BRAF mutations include heterogenous melanoma populations including those with mucosal melanomas which are well documented to typically have a different molecular profile [26]. We observed BRAF mutations in just 10 (11.2%) cases, all of which were in V600E GTG>GAG, confirming the previously reported markedly decreased incidence of BRAF mutations in cases of cutaneous melanoma in Ireland.
Compared with patients with BRAF WT melanoma, those with BRAF-mutated melanoma have reportedly been more often younger and have tumors that have a thinner Breslow thickness with superficial spreading or nodular histology and/or in anatomical regions without chronic sun damage [12, 27, 28]. In keeping with these findings, cases with BRAF mutations in our cohort trended toward being younger, and 90% of the BRAF-mutated melanomas were of the superficial spreading subtype (Table 2). However, the BRAF-mutated melanomas in our cohort trended toward being thicker. No differences were observed in the metastatic potential of BRAF mutant and BRAF WT tumors.
The second most commonly reported MAPK pathway aberration in melanoma is mutated NRAS, occurring in ~15–30% of internationally published cases [21, 27,28,29,30].
NRAS mutations have previously been documented as occurring in 21% of an Irish cohort (n = 21) [5] which was largely in keeping with the reported incidence in other populations [5, 8,9,10].
Our cohort had NRAS mutations in just 5 (5.49%) cases (4 of which had a Q61R mutation and 1 of which had a Q61K mutation). However, the relatively few detected mutations in NRAS likely preclude certainty on the significance of these findings.
As has been previously described in patients with melanomas harboring NRAS mutations, the patients trended toward being older (> 55 years), had thicker primary tumors, and had more frequent metastases than tumors associated with BRAF mutations or wild-type tumors [21]. NRAS mutations are reported more frequently present in higher chronic sun-induced damage melanomas [27]. However, the NRAS mutated melanomas in our cohort did not appear to trend toward occurring at more sun-exposed body parts than elsewhere.
Our study has a number of limitations. The sample size is relatively small. Technical and sample availability issues precluded testing of all variants in some cases. Although coverage of the most commonly observed mutations in the genes of interest was achieved, sequencing was performed on a limited number of targeted mutations. Therefore, the possibility exists that other mutations were present and not detected. We elected to examine primary melanomas and to observe progression over 10 years. However, testing primary tumors may underestimate the mutational burden observed at the time of progression.
Data on ethnic background is not routinely recorded in our pathology databases. However, data from the 2011 census demonstrates that the Irish population at the time was 84.5% White Irish (self-identified) and 94.3% White [31]. Given that our institution serves the more rural south-west of the country; the percentage of white Irish is likely even higher—a cohort typically considered to be of “Celtic ancestry”.
A low level of BRAF mutations (25%) has also been found among Scottish melanoma patients [23]. Red hair, resulting from an inactivating mutation in the MC1R gene, has long been associated with Celtic individuals and up to 75% of the Irish population carry a variant MC1R mutation [32].
It has been shown that the introduction of BRAF V600E mutation into mice carrying the Mc1r mutation leads to a high incidence of invasive melanomas without providing or inducing additional gene aberrations or ultraviolet exposure [33]. Therefore, it has been hypothesized that BRAF mutations in the Celtic population might be reduced as a cause of genetic drift or natural selection to protect this population from melanoma [5]. However, the high incidence of BRAF-mutated melanomas has been observed in fair-skinned individuals in countries such as the USA and Australia [8,9,10,11,12,13,14,15]. A significant number of these individuals are likely to be descended from Celtic ancestors raising uncertainty as to whether genetic predisposition is the (or at least the only) factor at play here.
Effects of the changing pattern of sun exposure in the Irish population may result in differences in the molecular patterns of melanomas in this cohort in the future. With the increasing industrialization of the country and increased availability of cheap air travel, beach holidays abroad in more southern latitudes have become a common experience. This relatively elderly population from 2012 may be more reflective of melanomas that developed in the more traditional exposure pattern.
Conclusion
These findings suggest that the Irish population has a markedly lower incidence of BRAF and NRAS mutations in melanomas than that previously reported in other population cohorts and will therefore potentially benefit less from the success of BRAF and MEK inhibitor therapy as well as any future NRAS-targeted treatments.
The findings in our study have considerable relevance to those treating melanoma in the Irish population and should be considered at a national level when developing strategies for treatment planning, budgets, and involvement in clinical trials because there will likely be more reliant on immune checkpoint inhibition as a treatment strategy in our cohort than is observed internationally.
Further investigation of the possible genetic underpinnings of our findings is warranted.
Given the large Irish diaspora internationally, these findings may have relevance in a wide number of international practice settings.
References
https://www.ncri.ie/publications/cancer-trends-and-projections/cancer-projections-ireland-2015-%E2%80%93-2040. Accessed January 2024
Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107–114. https://doi.org/10.1056/NEJMoa1203421
Cormican D, Kennedy C, Murphy S, Werner R, Power DG, Heffron CCBB (2019) High concordance of BRAF mutational status in matched primary and metastatic melanoma. J Cutan Pathol 46(2):117–122. https://doi.org/10.1111/cup.13393
O’Brien O, Lyons T, Murphy S, Feeley L, Power D, Heffron CCBB (2017) BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods. J Clin Pathol 70(11):935–940. https://doi.org/10.1136/jclinpath-2017-204367
van den Hurk K, Balint B, Toomey S et al (2015) High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients. Melanoma Res 25(3):189–199. https://doi.org/10.1097/CMR.0000000000000149
Nagore E, Requena C, Traves V et al (2014) Prognostic value of BRAF mutations in localized cutaneous melanoma. J Am Acad Dermatol 70(5):858–62.e622. https://doi.org/10.1016/j.jaad.2013.10.064
Lopez-Martin JA, Arance Fernández A, Ríos-Martín JJ et al (2020) Frequency and clinicopathological profile associated with Braf mutations in patients with advanced melanoma in Spain. Transl Oncol 13(6):100750. https://doi.org/10.1016/j.tranon.2020.100750
Thomas NE, Edmiston SN, Alexander A et al (2015) Association between NRAS and BRAF mutational status and melanoma-specific survival among patients with higher-risk primary melanoma [published correction appears in JAMA Oncol. 2015 Jun;1(3):285]. JAMA Oncol 1(3):359–368. https://doi.org/10.1001/jamaoncol.2015.0493
Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG (2006) Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 126(1):154–160. https://doi.org/10.1038/sj.jid.5700026
Jakob JA, Bassett RL Jr, Ng CS et al (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 118(16):4014–4023. https://doi.org/10.1002/cncr.26724
Wolfe AR, Chablani P, Siedow MR et al (2021) BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma. Radiat Oncol 16(1):181. Published 2021 Sep 18. https://doi.org/10.1186/s13014-021-01903-5
Long GV, Menzies AM, Nagrial AM et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29(10):1239–1246. https://doi.org/10.1200/JCO.2010.32.4327
Carlino MS, Haydu LE, Kakavand H et al (2014) Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer 111(2):292–299. https://doi.org/10.1038/bjc.2014.287
Menzies AM, Haydu LE, Visintin L et al (2012) Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18(12):3242–3249. https://doi.org/10.1158/1078-0432.CCR-12-0052
Thomas NE, Edmiston SN, Orlow I et al (2018) Inherited genetic variants associated with melanoma BRAF/NRAS subtypes. J Invest Dermatol 138(11):2398–2404. https://doi.org/10.1016/j.jid.2018.04.025
Ekedahl H, Cirenajwis H, Harbst K et al (2013) The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol 169(5):1049–1055. https://doi.org/10.1111/bjd.12504
Edlundh-Rose E, Egyházi S, Omholt K et al (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16(6):471–478. https://doi.org/10.1097/01.cmr.0000232300.22032.86
Aksenenko MB, Kirichenko AK, Ruksha TG (2015) Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma. Pathol Res Pract 211(7):521–527. https://doi.org/10.1016/j.prp.2015.03.005
Schlaak M, Bajah A, Podewski T et al (2013) Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients. Br J Dermatol 168(4):708–716. https://doi.org/10.1111/bjd.12140
Meckbach D, Bauer J, Pflugfelder A et al (2014) Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma. PLoS One 9(1):e86194. Published 2014 Jan 24. https://doi.org/10.1371/journal.pone.0086194
Colombino M, Capone M, Lissia A et al (2012) BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30(20):2522–2529. https://doi.org/10.1200/JCO.2011.41.2452
Inumaru JS, Gordo KI, Fraga Junior AC et al (2014) Analysis of the BRAF V600E mutation in primary cutaneous melanoma. Genet Mol Res 13(2):2840–2848. Published 2014 Jan 22. https://doi.org/10.4238/2014.January.22.8
Lang J, MacKie RM (2005) Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 125(3):575–579. https://doi.org/10.1111/j.0022-202X.2005.23833.x
Yaman B, Akalin T, Kandiloğlu G (2015) Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma. Am J Dermatopathol 37(5):389–397. https://doi.org/10.1097/DAD.0000000000000241
Web site: https://www.graphpad.com/. Accessed January 2024
Pracht M, Mogha A, Lespagnol A et al (2015) Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. J Eur Acad Dermatol Venereol 29(8):1530–1538. https://doi.org/10.1111/jdv.12910
Hayward NK, Wilmott JS, Waddell N et al (2017) Whole-genome landscapes of major melanoma subtypes. Nature. 545(7653):175–180. https://doi.org/10.1038/nature22071
Liu W, Kelly JW, Trivett M et al (2007) Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 127(4):900–905. https://doi.org/10.1038/sj.jid.5700632
Catalogue of somatic mutations in cancer (COSMIC). http://www.sanger.ac.uk/cosmic.
Fedorenko IV, Gibney GT, Smalley KS (2013) NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene. 32(25):3009–3018. https://doi.org/10.1038/onc.2012.453
https://doi.org/10.6004/jnccn.2019.0018 (accessed November 2023)
Smith R, Healy E, Siddiqui S et al (1998) Melanocortin 1 receptor variants in an Irish population. J Invest Dermatol 111(1):119–122. https://doi.org/10.1046/j.1523-1747.1998.00252.x
Mitra D, Luo X, Morgan A et al (2012) An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 491(7424):449–453. https://doi.org/10.1038/nature11624
Funding
Open Access funding provided by the IReL Consortium. The authors wish to acknowledge University College Cork School of Medicine Translational Research Access Programme (TRAP) for the provided funding.
Author information
Authors and Affiliations
Contributions
Dr G Neville conceived and designed the analysis, collected the data, performed the analysis, and drafted the paper. Dr B Marzario – collected the data and reviewed and contributed to the paper. Mr D Shilling contributed data and analysis tools, performed the analysis, and reviewed and contributed to the paper. Dr C Heffron and Dr C Hand conceived and designed the analysis, collected the data, contributed data and analysis tools, performed the analysis, and reviewed and contributed to the paper.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Ethical approval for this study was granted by the local institutional ethical review board.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Neville, G., Marzario, B., Shilling, D. et al. Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma. Virchows Arch 484, 475–479 (2024). https://doi.org/10.1007/s00428-023-03732-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-023-03732-1